Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

Conclusion: Adequate frontline treatment policy is vital for achieving an optimal balance between efficacy and toxicity. Current staging systems have a weak correlation with metabolic tumor burden: one-third of those recognized as advanced stage have the low burden, and vice versa about a half of intermediate-risk pts have high tumor burden. Combination of TMTV/TLG and cytokines can be currently used for decision making in borderline stage cases and probably could serve as a backbone for a new staging system in the future.Acknowledgement: IGA_LF_2018_004, MH CZ-DRO (FNOL, 00098892)DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Prochazka, V. K., Henzlova, L., Lukasova, M., Hanackova, V., Kriegova, E., Mikulkova, Z., Gabcova, G., Minarik, J., Sykorova, A., Krcalova, E., Dolezal, J., Koranda, P., Papajik, T. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster II Source Type: research